Article

Weekly Webinar Series Part 6: Managing Lung Cancer Patients Through the COVID-19 Pandemic

Author(s):

In part 6 of our weekly COVID-19 Webinar Series, our panel of experts will share the latest updates and insights on the novel coronavirus. Join us Wednesday, April 29, 2020 at 8 PM EST.

Date/Time: Wednesday, April 29, 2020 at 8 PM EDT

In part 6 of our weekly COVID-19 Webinar Series, Nathan Pennell, MD, PhD; Stephen Liu, MD; Charu Aggarwal, MD, MPH; H. Jack West, MD: and special guest speaker, Brendon Stiles, MD; will share the latest updates and insights on the novel coronavirus.

Click here to register today!

Speakers:

Associate Professor; Director, Lung Cancer, Medical Oncology Program at Cleveland Clinic, Cleveland, Ohio

Associate Professor of Medicine; Director, Thoracic Oncology at Georgetown University, Washington, DC

Leslye M. Heisler Assistant; Professor of Medicine at University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania

Associate Clinical Professor in Medical Oncology; Executive Director, Employer Services at City of Hope Comprehensive Cancer Center, Irwindale, CA

Brendon Stiles, MD, Special Guest Speaker; Associate Professor of Cardiothoracic Surgery, Weill Cornell Medical College and Associate Attending Cardiothoracic Surgeon at NewYork-Presbyterian Hospital

Related Videos
Daniel E. Haggstrom, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for NVL-655 in ALK-positive NSCLC and other ALK-positive solid tumors.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss testing for ALK-positive and ROS1-positive non–small cell lung cancer.
Nicolas Girard, MD